Expression of transforming growth factor-beta 3 by embryonal carcinoma cells, parietal endoderm-like cells and early mouse embryos.
Utilizing the technique of reverse transcription-polymerase chain reaction (RT-PCR), we have examined the expression of transforming growth factor-beta 3 (TGF-beta 3) by embryonal carcinoma (EC) cells, EC-derived differentiated cells and early mammalian embryos. Using a TGF-beta bioassay, we determined that PYS-2 cells express considerable TGF-beta activity that cannot be completely neutralized by antibodies specific for TGF-beta 1 and TGF-beta 2. We also have determined that PYS-2 cells, as well as F9 EC cells and their differentiated cells, express transcripts for TGF-beta 3. In addition, we have determined that blastocysts, cultured for three days in serum-containing medium, express TGF-beta 3 transcripts. Thus, our data suggest that expression of TGF-beta 3 is initiated during early stages of mammalian development.
Campbell
W J
WJ
Eppley Institute for Cancer Research and Allied Diseases, University of Nebraska Medical Center, Omaha 68198.
Kelly
D
D
Rizzino
A
A
D000818:Animals; D001755:Blastocyst / Q000378:metabolism; D003994:Bucladesine / Q000494:pharmacology; D002454:Cell Differentiation / Q000187:drug effects; D002460:Cell Line; D004622:Embryo, Mammalian; D054278:Embryonal Carcinoma Stem Cells; D004707:Endoderm / Q000378:metabolism*; D015870:Gene Expression; D051379:Mice; D009028:Morula / Q000378:metabolism; D014411:Neoplastic Stem Cells / Q000378:metabolism*; D016133:Polymerase Chain Reaction; D014158:Transcription, Genetic; D016212:Transforming Growth Factor beta / Q000096:biosynthesis* / Q000235:genetics; D014212:Tretinoin / Q000494:pharmacology
D016212:Transforming Growth Factor beta; D014212:Tretinoin; D003994:Bucladesine